PMID- 38264426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240125
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 27
IP  - 2
DP  - 2024 Feb
TI  - A novel approach for transforming breast cancer stem cells into endothelial 
      cells.
PG  - 74
LID - 10.3892/etm.2023.12362 [doi]
LID - 74
AB  - Tumor vascular endothelial cells play a pivotal in the tumor microenvironment, 
      influencing the proliferation, invasion, and metastasis of tumor progression. The 
      present study investigated a novel method for inducing the transformation of 
      breast cancer stem cells into endothelial cells, providing a cellular model 
      investigating anti-angiogenic mechanisms in vitro. The breast cancer cell line 
      MCF-7 was used, and the expression of CD133 was initially detected using flow 
      cytometry. CD133(+) breast cancer cells were purified using immunomagnetic bead 
      sorting technology, yielding an MCF-7(CD133+) subpopulation. The proliferation 
      ability of these cells was assessed using an MTT assay, while their microsphere 
      formation ability was evaluated using a microsphere formation assay. 
      Post-transformation in an optimized endothelial cell culture medium, expression 
      of endothelial cell markers CD31 and CD105 were detected using flow cytometry. 
      Endothelial cell tube formation assays and DiI-labeled acetylated low-density 
      lipoprotein (DiI-Ac-LDL) assays were employed to analyze the endothelial cell 
      function of the MCF-7(CD133+) cells. MDM2/CEN12 gene amplification was detected 
      through fluorescence in situ hybridization (FISH). The MCF-7 breast cancer cell 
      line exhibited 1.7+/-0.3% trace cells expressing the stem cell surface marker 
      CD133. After anti-CD133 immunomagnetic bead sorting, MCF-7(CD133+) and 
      MCF-7(CD133-) subpopulation cells were obtained, with CD133 expression rates of 
      85.6+/-2.8 and 0.18+/-0.08%, respectively. MTT assay results demonstrated that, after 
      7 days, the proliferation rate of MCF-7(CD133+) cells was significantly higher 
      compared with MCF-7(CD133-) cells. MCF-7(CD133+) subpopulation cells displayed 
      strong stem cell characteristics, growing in suspension in serum-free media and 
      forming tumor cell spheres. In contrast, MCF-7(CD133-) cells failed to form 
      microspheres. After culturing cells in endothelial cell differentiation and 
      maintenance media, the percentage of MCF-7(CD133+) cells before and after 
      endothelial cell culture was 0.3+/-0.16 and 81.4+/-8.37% for CD31(+) cells and 
      0.2+/-0.08 and 83.8+/-7.24% for CD105(+) cells, respectively. Vascular-like structure 
      formation and Ac-LDL phagocytosis with red fluorescence in the tube formation 
      assays confirmed endothelial cell function in the MCF-7(CD133+) cells. FISH was 
      used to verify MDM2/CEN12 gene amplification in the induced MCF-7(CD133+) cells, 
      indicating tumor cell characteristics. The modified endothelial cell 
      transformation medium effectively induced differentiated tumor stem cells to 
      express vascular endothelial cell markers and exhibit endothelial functions, 
      ideal for in vitro anti-angiogenesis research.
CI  - Copyright: (c) Mao et al.
FAU - Mao, Qi-Qi
AU  - Mao QQ
AD  - Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili 
      Hospital, Ningbo, Zheijiang 315040, P.R. China.
FAU - Ji, Xiao-Chun
AU  - Ji XC
AD  - Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili 
      Hospital, Ningbo, Zheijiang 315040, P.R. China.
FAU - Zhang, Jia-Nan
AU  - Zhang JN
AD  - Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili 
      Hospital, Ningbo, Zheijiang 315040, P.R. China.
FAU - Teng, Wei-Feng
AU  - Teng WF
AD  - Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili 
      Hospital, Ningbo, Zheijiang 315040, P.R. China.
FAU - Zhou, Shao-Cheng
AU  - Zhou SC
AD  - Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili 
      Hospital, Ningbo, Zheijiang 315040, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20231221
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC10804376
OTO - NOTNLM
OT  - CD133
OT  - breast cancer
OT  - endothelial cells
OT  - transformation
OT  - tumor stem cells
COIS- The authors declare that they have no competing interests.
EDAT- 2024/01/24 06:43
MHDA- 2024/01/24 06:44
PMCR- 2023/12/21
CRDT- 2024/01/24 03:52
PHST- 2023/08/19 00:00 [received]
PHST- 2023/11/27 00:00 [accepted]
PHST- 2024/01/24 06:44 [medline]
PHST- 2024/01/24 06:43 [pubmed]
PHST- 2024/01/24 03:52 [entrez]
PHST- 2023/12/21 00:00 [pmc-release]
AID - ETM-27-2-12362 [pii]
AID - 10.3892/etm.2023.12362 [doi]
PST - epublish
SO  - Exp Ther Med. 2023 Dec 21;27(2):74. doi: 10.3892/etm.2023.12362. eCollection 2024 
      Feb.